Recent developments include a strategic technology transfer agreement with Oramed, leadership changes, regulatory approvals, and financial results announcements.

• In January 2026, Oramed agreed to transfer POD technology to Lifeward in exchange for a 49.9% beneficial ownership interest in Lifeward [N1].
• Lifeward achieved European MDR certification for its ReWalk 7 Personal Exoskeleton in September 2025, enabling commercial distribution in the EU [N4].
• Almog Adar was appointed as Lifeward's Chief Financial Officer in August 2025, with shares rising 4% pre-market following the announcement [N6].
• The company reported a net loss and revenue shortfall in Q2 2025, continuing a trend of quarterly losses [N5].
• HC Wainwright & Co. maintained a buy recommendation for Lifeward in November 2025, reflecting ongoing analyst interest [N2].
• Lifeward held its Q3 2025 earnings call in November 2025, providing updates on financial performance and business operations [N3].

Lifeward has secured key regulatory approvals for its ReWalk exoskeleton products, including recent FDA 510(k) clearances and European MDR certification, enabling commercial distribution in major markets. The transition to in-house manufacturing for ReWalk products may provide greater control over quality and cost efficiencies. Strategic partnerships, such as the technology transfer agreement with Oramed, and leadership appointments like the new CFO, indicate active management of growth and operational execution. The company has demonstrated ongoing product development and market engagement through investor conferences and public offerings, supporting its business expansion efforts.

Lifeward faces substantial financial challenges, including a significant accumulated deficit and net losses, with liquidity ratios indicating limited cash resources relative to current liabilities. There is substantial doubt about the company's ability to continue as a going concern without additional financing, which is subject to conditions and market factors. Manufacturing transitions carry execution risks, including supplier dependencies and regulatory compliance challenges. The company operates in a highly regulated environment with potential for costly enforcement actions, recalls, and compliance burdens. Market adoption may be constrained by limited reimbursement policies and the need for broader clinical validation. These factors collectively pose risks to the company's operational and financial stability.

Lifeward's moat is primarily based on its regulatory clearances and certifications for its powered exoskeleton devices, including FDA de novo classification and European MDR certification, which create barriers to entry for competitors. The company's proprietary technology, ongoing product development, and established manufacturing partnerships contribute to its competitive position. Additionally, its compliance with complex regulatory and quality management systems, and its relationships with healthcare providers and payors, support its market presence. However, the company faces risks from regulatory changes, manufacturing transitions, and the need for continued innovation and reimbursement acceptance, which may impact its competitive advantage.

• Regulatory Compliance Risks: Lifeward must comply with FDA, EU MDR, and other international regulations, including quality management systems and post-market surveillance. Non-compliance could lead to enforcement actions, product recalls, fines, or suspension of marketing rights [S1].
• Manufacturing and Supply Chain Risks: The transition to in-house manufacturing for ReWalk products and reliance on third-party suppliers and contract manufacturers pose risks related to production capacity, quality control, and timely delivery of components [S1].
• Financial Risks and Going Concern: The company has an accumulated deficit and reported net losses, with liquidity ratios indicating limited cash reserves. There is substantial doubt about its ability to continue as a going concern without additional financing, which is subject to closing conditions and market factors [S1].
• Legal and Compliance Risks: Lifeward is subject to anti-bribery, healthcare fraud and abuse laws, and data privacy regulations such as HIPAA and GDPR. Violations could result in significant penalties, litigation costs, and reputational damage [S1].
• Market Adoption and Reimbursement Risks: Limited large-scale clinical trial data and lack of broad uniform reimbursement policies may slow adoption of Lifeward's products by healthcare providers and payors, impacting sales growth [S1].

• Lifeward Ltd. develops and markets powered exoskeleton medical devices, including the ReWalk Personal Exoskeleton and ReStore device, intended to assist individuals with spinal cord injuries and stroke-related hemiplegia or hemiparesis respectively [S1].
• The ReWalk Personal Exoskeleton received FDA de novo classification in 2014 as a Class II powered exoskeleton device, with subsequent 510(k) clearances in March 2023 for stair and curb functionality and in March 2025 for the ReWalk 7 Personal Exoskeleton model [S1].
• The ReStore device received FDA 510(k) clearance in June 2019 for use in rehabilitation institutions under therapist supervision [S1].
• In the European Union, Lifeward's ReWalk 7 Personal Exoskeleton received MDR certification in September 2025, while prior models remain CE marked under transitional provisions; the ReStore device sales ceased in the EU in May 2024 due to regulatory changes [S1].
• Lifeward transitioned manufacturing of ReWalk products in Q2 2025 to in-house operations, terminating its contract with Sanmina Corporation, and continues to rely on Cirtronics for manufacturing of AlterG products and component sourcing [S1].
• The company is subject to extensive regulatory compliance requirements including FDA Quality Management System Regulation (QMSR), ISO 13485:2016, and EU MDR, with periodic inspections and potential enforcement actions for non-compliance [S1].
• Lifeward faces risks related to manufacturing capacity, supplier dependencies, regulatory compliance, and product liability, including potential recalls and enforcement actions [S1].
• The company is subject to various U.S. and international laws including anti-bribery (FCPA, UK Bribery Act), healthcare fraud and abuse laws, and data privacy regulations such as HIPAA, EU GDPR, and state-level privacy laws, which impose compliance costs and risks [S1].
• Lifeward reported fiscal year 2025 revenue of $22.0 million and a net loss of $19.9 million, with basic and diluted EPS of -$17.16 as of December 31, 2025 [S1].
• Liquidity ratios as of December 31, 2025, include a current ratio of 1.31 and a cash ratio of 0.18, with cash and equivalents totaling approximately $2.17 million [S1].
• The company has an accumulated deficit of approximately $284.7 million as of December 31, 2025, and substantial doubt exists about its ability to continue as a going concern without additional financing [S1].
• In January 2026, Lifeward entered a securities purchase agreement with Oramed and others to issue senior secured convertible notes and warrants, subject to closing conditions including sales performance or share price thresholds [S1].
• Recent news highlights include Oramed transferring POD technology to Lifeward in exchange for a 49.9% ownership interest, European approval for the ReWalk 7 exoskeleton, and leadership changes such as the appointment of Almog Adar as CFO [N1][N4][N6].
• Lifeward has conducted public offerings raising $2.6 million and participated in investor conferences, with ongoing quarterly earnings reports indicating losses and revenue shortfalls relative to estimates [N5][N12][N2][N3].